Recently Featured

British Patients Risking Safety by Turning to Unregulated Weight Loss Drugs, Survey Reveals

April 28, 2026
Recent survey findings indicate that a significant number of British patients are resorting to unregulated weight loss medications available online, driven by escalating drug prices and prolonged prescription wait times. This trend raises serious concerns about the safety and efficacy of these products, as many may contain harmful substances or lack proper dosage information. The…

Lilly boosts ‘in vivo’ cell therapy capabilities with Kelonia buyout

April 28, 2026
Worth up to $7 billion, Lilly’s acquisition of Kelonia marks a significant expansion of its capabilities in the cell therapy sector, particularly for treatments targeting multiple myeloma currently in early-stage testing. This strategic move follows Lilly’s recent investments in similar technologies, underscoring its commitment to advancing innovative therapeutic solutions. The acquisition positions Lilly to enhance…

Boehringer Ingelheim to expand its AI footprint in UK, in £150M investment

April 27, 2026
Boehringer Ingelheim is set to enhance its artificial intelligence capabilities in the UK with a significant investment of £150 million over the next decade. The pharmaceutical giant plans to establish a new AI hub in central London, signaling a strategic move to leverage advanced technologies in drug development and healthcare solutions. This expansion reflects a…

Ongoing Cases